Therapy Directory

Antibody-drug conjugates clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Antibody-drug conjugates as a study intervention. Browse Antibody-drug conjugates recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

503

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Cancer, Solid Tumor, Solid Tumor Cancer, Oncology, uPAR-positive Solid Tumor, Urokinase Plasminogen Activator Receptor-positive Solid Tumor
Interventions: MNPR-101-PCTA-177Lu; Biological
Lead sponsor: Monopar Therapeutics; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Solid Tumor, Solid Tumor, Adult
Interventions: MNPR-101-DFO*-89Zr; Diagnostic Test
Lead sponsor: Monopar Therapeutics; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
Interventions: IMGN632; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 13 more

Conditions: Participants With Advanced Solid Tumor Malignancies
Interventions: VBC101; Drug
Lead sponsor: VelaVigo Bio Inc; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas + 2 more

Conditions: Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic Endometrial Cancer
Interventions: ARR-002; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Orlando, Florida • Boston, Massachusetts • Nashville, Tennessee + 3 more

Conditions: Advanced Solid Tumor, Advanced Lymphoma
Interventions: CS5001, Rituximab, Gemcitabine, Oxaliplatin, Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug · Biological
Lead sponsor: CStone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: East Setauket, New York • New York, New York • Dallas, Texas

Conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
Interventions: Tafasitamab, Polatuzumab vedotin, Glofitamab, Obinutuzumab; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Advanced Solid Tumors
Interventions: VBC108; Drug
Lead sponsor: VelaVigo Bio Inc; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Duarte, California • Grand Rapids, Michigan • New York, New York + 2 more

Conditions: CNS Tumor, Solid Tumor, Relapsed Cancer, Refractory Cancer, Pediatric Cancer
Interventions: Bulk RNA Sequencing, Immunohistochemistry (IHC); Diagnostic Test
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 30 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Endometrial Cancer
Interventions: Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 43
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more

Conditions: Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer
Interventions: STRO-004, Pembrolizumab; Drug
Lead sponsor: Sutro Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Trastuzumab Deruxtecan, Datopotamab Deruxtecan; Drug
Lead sponsor: Ana C Garrido-Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more

About this Antibody-drug conjugates clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Antibody-drug conjugates as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Antibody-drug conjugates.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Antibody-drug conjugates clinical trials

Filter and sort this therapy

Live official records

MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

About this Antibody-drug conjugates clinical trials directory page